157 related articles for article (PubMed ID: 7753548)
1. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss.
Blyth K; Terry A; O'Hara M; Baxter EW; Campbell M; Stewart M; Donehower LA; Onions DE; Neil JC; Cameron ER
Oncogene; 1995 May; 10(9):1717-23. PubMed ID: 7753548
[TBL] [Abstract][Full Text] [Related]
2. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
Baxter EW; Blyth K; Cameron ER; Neil JC
J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
[TBL] [Abstract][Full Text] [Related]
3. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
[TBL] [Abstract][Full Text] [Related]
4. The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice.
Curtis DJ; Robb L; Strasser A; Begley CG
Oncogene; 1997 Dec; 15(24):2975-83. PubMed ID: 9416841
[TBL] [Abstract][Full Text] [Related]
5. p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice.
Landesman-Bollag E; Channavajhala PL; Cardiff RD; Seldin DC
Oncogene; 1998 Jun; 16(23):2965-74. PubMed ID: 9662328
[TBL] [Abstract][Full Text] [Related]
6. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
7. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc.
Vaillant F; Blyth K; Terry A; Bell M; Cameron ER; Neil J; Stewart M
Oncogene; 1999 Nov; 18(50):7124-34. PubMed ID: 10597314
[TBL] [Abstract][Full Text] [Related]
8. Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region.
Stewart M; Cameron E; Campbell M; McFarlane R; Toth S; Lang K; Onions D; Neil JC
Int J Cancer; 1993 Apr; 53(6):1023-30. PubMed ID: 8473043
[TBL] [Abstract][Full Text] [Related]
9. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging.
Blyth K; Terry A; Mackay N; Vaillant F; Bell M; Cameron ER; Neil JC; Stewart M
Oncogene; 2001 Jan; 20(3):295-302. PubMed ID: 11313958
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic and cellular events during radiation-induced thymic lymphomagenesis in the p53 heterozygous (+/-) B10 mouse.
Tanaka K; Watanabe K; Mori M; Kamisaku H; Tsuji H; Hirabayashi Y; Inoue T; Yoshida K; Aizawa S
Int J Radiat Biol; 2002 Mar; 78(3):165-72. PubMed ID: 11869471
[TBL] [Abstract][Full Text] [Related]
11. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.
Harvey M; Vogel H; Morris D; Bradley A; Bernstein A; Donehower LA
Nat Genet; 1995 Mar; 9(3):305-11. PubMed ID: 7773294
[TBL] [Abstract][Full Text] [Related]
12. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis.
Hsu B; Marin MC; el-Naggar AK; Stephens LC; Brisbay S; McDonnell TJ
Oncogene; 1995 Jul; 11(1):175-9. PubMed ID: 7624125
[TBL] [Abstract][Full Text] [Related]
13. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
[TBL] [Abstract][Full Text] [Related]
14. Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice.
Ward JM; Tadesse-Heath L; Perkins SN; Chattopadhyay SK; Hursting SD; Morse HC
Lab Invest; 1999 Jan; 79(1):3-14. PubMed ID: 9952106
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles.
Renard CA; Fourel G; Bralet MP; Degott C; De La Coste A; Perret C; Tiollais P; Buendia MA
Oncogene; 2000 May; 19(22):2678-86. PubMed ID: 10851067
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice.
Blyth K; Stewart M; Bell M; James C; Evan G; Neil JC; Cameron ER
Oncogene; 2000 Feb; 19(6):773-82. PubMed ID: 10698495
[TBL] [Abstract][Full Text] [Related]
17. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice.
Reese JS; Allay E; Gerson SL
Oncogene; 2001 Aug; 20(38):5258-63. PubMed ID: 11536039
[TBL] [Abstract][Full Text] [Related]
19. Fas-independent apoptosis in T-cell tumours induced by the CD2-myc transgene.
Cameron ER; Morton J; Johnston CJ; Irvine J; Bell M; Onions DE; Neil JC; Campbell M; Blyth K
Cell Death Differ; 2000 Jan; 7(1):80-8. PubMed ID: 10713723
[TBL] [Abstract][Full Text] [Related]
20. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
